Adaptimmune Therapeutics plc (Nasdaq: ADAP) announced that its amended protocol using its NY-ESO SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE